Glycologix
1 known investors
Glycologix develops biopolymers for treating soft tissue damage, specifically targeting interstitial cystitis and bladder pain syndrome in a clinical-stage biotech model. The company's compounds mimic natural proteoglycans to protect and repair affected tissues.
BiotechDigital HealthMedical Devices
Investors · 1
In the news
- Development of a unique crosslinked glycosaminoglycan for soft tissue repair: Treatment of interstitial cystitis/bladder pain syndrome | PLOS Onejournals.plos.org · 2025
- Glycologix - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2023
- Glycologix - 2026 Funding Rounds & List of Investors - Tracxntracxn.com · 2023
- Let’s Talk About Soft Tissues (no, not Kleenex) | by Nathaniel Harding | Cortado Ventures Insights | Mediummedium.com · 2022
- News - Glycologixglycologix.com · 2022
- NSIV Member Spotlight — Glycologix | InnoVenture Labsnsiv.org · 2018